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with congenital hypogonadotropic hypogonadism
using a web-based needs assessment: implications
for online interventions and peer-to-peer support
Andrew A Dwyer1*, Richard Quinton2, Diane Morin3 and Nelly Pitteloud4Abstract
Background: Patients with rare diseases such as congenital hypogonadotropic hypogonadism (CHH) are dispersed,
often challenged to find specialized care and face other health disparities. The internet has the potential to reach
a wide audience of rare disease patients and can help connect patients and specialists. Therefore, this study aimed
to: (i) determine if web-based platforms could be effectively used to conduct an online needs assessment of dispersed
CHH patients; (ii) identify the unmet health and informational needs of CHH patients and (iii) assess patient acceptability
regarding patient-centered, web-based interventions to bridge shortfalls in care.
Methods: A sequential mixed-methods design was used: first, an online survey was conducted to evaluate health
promoting behavior and identify unmet health and informational needs of CHH men. Subsequently, patient focus
groups were held to explore specific patient-identified targets for care and to examine the acceptability of possible
online interventions. Descriptive statistics and thematic qualitative analyses were used.
Results: 105 male participants completed the online survey (mean age 37 ± 11, range 19–66 years) representing
a spectrum of patients across a broad socioeconomic range and all but one subject had adequate healthcare
literacy. The survey revealed periods of non-adherence to treatment (34/93, 37%) and gaps in healthcare (36/87,
41%) exceeding one year. Patient focus groups identified lasting psychological effects related to feelings of
isolation, shame and body-image concerns. Survey respondents were active internet users, nearly all had sought
CHH information online (101/105, 96%), and they rated the internet, healthcare providers, and online community
as equally important CHH information sources. Focus group participants were overwhelmingly positive regarding
online interventions/support with links to reach expert healthcare providers and for peer-to-peer support.
Conclusion: The web-based needs assessment was an effective way to reach dispersed CHH patients. These
individuals often have long gaps in care and struggle with the psychosocial sequelae of CHH. They are highly
motivated internet users seeking information and tapping into online communities and are receptive to novel
web-based interventions addressing their unmet needs.
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Patients affected by rare diseases are dispersed and face
a variety of challenges including lack of specialized care,
delays in diagnosis, negative social consequences and
other psychosocial burdens. The European Organization
of Rare Diseases has previously reported a variety of ob-
stacles these patients face [1]. Many of these are critical
social determinants of health that place rare disease
patients in the realm of health disparities [2]. Further,
beyond disease and symptom burden, the rarity of the
condition can result in patients and families feeling
marginalized. In addition, the psychosocial impact of
perceived invisibility, isolation, and feelings of powerless-
ness can have significant deleterious impact on quality
of life [3-5]. One way that patients and families have
overcome this is by embracing technology to access in-
formation and connect with other patients online [6,7].
Advances in information technology and communications
are creating cultural shifts and are changing how people
develop expertise. These trends have important implica-
tions for healthcare systems and particular relevance for
empowering patients dealing with rare diseases [8].
Congenital hypogonadotropic hypogonadism (CHH,
ORPHA174590) is a rare, genetic, endocrine disorder
which is clinically characterized by incomplete/absent
puberty and infertility as a result of a deficiency of go-
nadotropin releasing hormone. When it occurs with an
absent sense of smell it is termed Kallmann syndrome
(KS, ORPHA478). While incidence is difficult to assess,
it is estimated at one in 4,000-10,000 based on a study
of French conscripts [9]. Additionally, it is 2–5 times less
frequent in females than in males though this gender dis-
cordance may represent a bias of ascertainment [10,11].
Most cases are sporadic, consistent with a condition which
impairs fertility, yet approximately a third of cases display
a familial pattern of inheritance. CHH is clinically het-
erogeneous and may occur with variable reproductive
(e.g. undescended testes with/without micropenis) and
non-reproductive phenotypes such as eye/ear anomalies
(including sensorineural deafness), cleft lip/palate, skeletal
anomalies, osteoporosis, metabolic disturbances and renal
agenesis [11].
As with other rare disorders, CHH patients often ex-
perience delays in diagnosis. For these individuals, the
absent sexual development of CHH becomes increas-
ingly apparent as peers and younger siblings advance
through puberty while they remain in a preadolescent
state. This experience can have significant emotional
and psychological consequences - as depicted in an early
case series [12] and reiterated in a recent patient ac-
count [13]. Indeed, studies of newly diagnosed adoles-
cent males with CHH indicate higher levels of anxiety
and depressive symptoms compared to peers [14,15].
However, the long-term impact on CHH patients hasnot been examined. Unlike many other orphan diseases,
there are effective treatments available. Hormone re-
placement therapy can induce development of sexual
characteristics and in most cases, fertility [16-18]. Cases
of spontaneous reversal has been documented [19], yet
patients typically require lifelong therapy. Importantly,
normalizing the serum hormone levels does not com-
pletely ameliorate the biopsychosocial effects that CHH
patients experience. A study of adolescent CHH patients
indicated improved mood after 6-months of treatment,
yet significant physical and emotional role difficulties
persisted compared to healthy peers [14]. These factors
may impede adherence to treatment which is a widely-
recognized and significant problem in healthcare, par-
ticularly in chronic disease, as an estimated 50% find it
challenging to meet prescribed regimens regardless of
disease, prognosis, or setting [20]. Patients with chronic
conditions provide approximately 95% of their care [21]
and thus, adherence problems can have important health
ramifications. Non-adherence in men with CHH causes
hormone levels plummet and patients become hypo-
gonadal, placing them at risk for osteoporosis, anemia and
metabolic problems such as insulin resistance [22-27]. A
study examining bone health of a cohort of 26 Finnish
patients indicated 35% of patients had non-adherence
periods exceeding 5 years [28]. So despite the availability
of effective treatments, there are seemingly other issues
diminishing CHH patients’ self-care practices. However,
we do not know the extent of problems with adherence
among the general population of CHH men nor do we
understand patients’ perceived barriers to adherence and
health promoting behavior.
Therefore, the aim of this study was threefold. First, to
examine the utility of web-based platforms for reaching
dispersed CHH patients and conducting an online needs
assessment. Second, to better define patterns of adherence
to treatment and unmet health and informational needs of
CHH patients. Third, to identify specific patient-reported
targets for care and assess the acceptability of launching
patient-centered e-health interventions to enhance self-
care and health promoting behavior.
Methods
This study utilized a community based participatory re-
search framework. This approach has previously been
put forth as a useful research model for empowering pa-
tients and overcoming health inequities [29]. As part of
a European network focused on CHH (COST Action
BM1105 [30]), partnerships with online patient commu-
nity leaders (i.e. moderators of online patient support
sites) were developed to contribute to the study design,
recruitment, and conduct of the study. We recognized
patients as experts and these partners were actively in-
volved in generating ideas as well as providing feedback,
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the questions and improve the language and clarity of the
survey and focus group questions. This descriptive, multi-
variate correlational needs assessment study employed a
sequential mixed-methods design. This approach (QUANT-
Qual) started with an online survey and statistical analysis of
the quantitative data (Figure 1). Subsequently, patient focus
groups were conducted and discussions were analyzed using
a qualitative data analysis. The intention behind employing
this mixed-methods approach was to provide a deeper ex-
ploration of the unmet health needs of CHH men than
would be possible by either method in isolation.
Men were targeted for recruitment as CHH is rare and
male cases are 2–5 times more common than female
cases [10,11]. Men 18–70 years of age diagnosed with
CHH [31] were included in the study. A random sam-
pling (40% of subjects) were contacted to confirm diag-
nosis and those outside of the age range or who had
other causes of hypogonadism were excluded from ana-
lyses. The study was publicized online via a closed/pri-
vate CHH social media group (Facebook), CHH forum
(chat room), a clinical trials registry [32], and the COST
Action website [30]. Focus groups were held in concert
with patient-support meetings that were planned jointly
by patient community leaders and study investigators.
First, the quantitative arm included an online survey
to collect demographic information and to assess
healthcare literacy, health information seeking patterns,
interactions with healthcare system/providers, and self-
reported adherence to treatment/healthcare (Additional
file 1). To assess healthcare literacy we used a self-report
method previously shown to correspond with lengthier
gold standard literacy tests [33,34]. Descriptive statistics,
Chi square and Pearson product moment coefficients
of correlation were performed on survey results. ToFigure 1 Study schema. Schematic depicting the sequential explanatory
conducted and statistical analysis performed. (B) Subsequently, qualitative
and identify potential explanatory mechanisms. Asterisks note study stagesevaluate the relative importance of the most frequently
used sources of CHH information we performed Kruskall-
Wallace one-way analysis of variance on ranks. SigmaStat
(Systat Software Inc., San Jose, California, USA) was
used for statistical analyses and a p < 0.05 was considered
significant.
Second, the qualitative arm involved patient focus
groups discussing issues and challenges related to living
with CHH, patient-reported coping strategies and the
acceptability of possible online interventions. Questions
were derived from Pender’s Health Promotion Model
[35] and developed with input from patient community
leaders. Focus group transcripts were analyzed using
NVivo10 (QSR International PSY Ltd., Melbourne
Australia). Briefly, thematic analysis (coding) was con-
ducted by two separate investigators (AD:DM) to identify
categories of responses and themes emerging from the
focus group discussions and discrepancies in coding as
well as emergent categories were discussed until reso-
lution was achieved. Iterative coding occurred until no
further themes are identified, suggesting a saturation
point has been reached. Additionally, connections between
coded terms were mapped to examine connections within
and between categories (i.e. whether or not certain themes
appear together repeatedly) and those arising frequently
and expansively were given particular emphasis [36].
The study was approved by the University of Lausanne
ethics committee and informed consent was obtained
from all participants. Participants in the online survey
provided an electronic, opt-in format consent while
focus group members provided written consent. All par-
ticipants received investigator contact information to
address questions/concerns and were given the option to
provide an email address if they agreed to be contacted
by the investigators for follow-up clarification.mixed-methods design. (A) First, a quantitative online survey was
focus groups were conducted to explore the survey findings in detail
involving participation of patient community leaders.
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Web-based platforms combined with community
partnerships are effective for conducting needs
assessment survey in dispersed patients
The survey was online for 7-months and received a total
of 230 hits. Of these, 105 (46%) were CHH men who
completed the survey and met inclusion criteria. To pro-
vide context, if one takes the incidence of CHH as
1/10,000, then recruiting 100 subjects would provide an
equivalent denominator of 1 million people. Thus, the
web-based recruitment was an effective way to reach this
dispersed population of CHH men. The sociodemo-
graphic information of the men responding to the
web-based survey is provided in Table 1. These partici-
pants varied in age from 19–66 years (mean 37 ± 11,
median 36), two thirds had received education beyond
high school/vocational training (69/105, 66%) and the
majority were employed (79/104, 76%) across a broad
spectrum of fields (Additional file 1). From the relatively
advanced age of survey respondents we suspect that
younger men with CHH may be lurking online to gather
information but may not yet feel emotionally secure
enough to discuss issues regarding their lack of sexual
development. A review of the email addresses voluntarily
provided by participants included email service providersTable 1 Sociodemographics of the CHH men completing
the online survey (n = 105)
Age (n = 105) n (%)
19–29 32 (30%)
30–39 39 (37%)
40–49 19 (18%)
50–59 11 (10%)
60+ 4 (4%)
Education (n = 105)
High school/vocational 36 (34%)
University 38 (36%)
Post-Graduate 31 (30%)
Employment (n = 104)
Working full-time 70 (67%)
Working part-time 9 (9%)
Unemployed 10 (10%)
Retired 6 (6%)
Student 9 (9%)
Relationship status (n = 104)
Married 38 (36%)
In a relationship 16 (15%)
Single 25 (24%)
Never been in a relationship 24 (23%)
Divorced 1 (1%)from North and South America, Europe, and Australasia
underscoring the global reach of online recruiting via
social media for rapidly reaching dispersed patients.
Studying orphan diseases presents a challenge in terms
of recruiting adequate numbers of widely dispersed pa-
tients [37,38]. Previously, online web-based question-
naires have proven a useful tool for reaching dispersed
populations [39] and advertising on social media plat-
forms can enhance patient recruitment efforts [40,41].
Instead of using online advertising, herein we developed
partnerships with online patient community leaders to
reach dispersed rare disease patients and utilized web-
based platforms for both recruitment and data collec-
tion. This was an effective way to reach a large audience
and conduct an online CHH needs assessment. Further,
such patient community partnerships may provide mul-
tiple bi-directional benefits including connecting pa-
tients with expert care and enhancing recruitment for
research/clinical trials.
CHH patients have long gaps in care
Nearly all the men (99/105, 94%) in the online survey
responded that they had received testosterone therapy
for CHH. Six men reported never having received testos-
terone; three men stated they had never been on treat-
ment (2/3 had been recently diagnosed) and the other 3
men had only received gonadotropin injections. In total,
only 24/93 (26%) of men reported never having a lapse
or gap in treatment (Figure 2). However, 37% (34/93) re-
ported having been off treatment for more than a year.
Survey respondents reported similar the periods when
asked about the longest duration without healthcare
(Additional file 1). No correlation was observed betweenDuration off treatment (months)
never <6 6-12 13-24 25-36 36+
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Figure 2 Adherence to treatment among CHHmen. Patient-reported
longest duration off treatment (n = 93). All men had been on treatment
for at least 12 months. Only 26% (24/93) of men reported never having
a gap in treatment (white bar). In total, 37% (34/93) had a lapse in
treatment of more than1 year.
Figure 3 Patient-reported challenges of CHH. Patient-reported
challenges represent targets for interventions. Focus group discussions
revealed two dominant themes relating to feelings of isolation and shame
(depicted by circles). These themes encompassed 4 consistent, inter-related
psychosocial challenges related to CHH low self-esteem, body image
concerns, feeling left behind by their lack of sexual development, and
issues related to anxiety and depression (depicted by diamonds). The
shapes are sized according to the frequency of patient comments and
overlaps and connected shapes identify co-occurring themes.
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nosis or lifetime duration of treatment. Importantly,
these gaps in treatment and care can have major health
impacts on patients. Hypogonadism causes decreased
libido, impaired sexual function and anemia and can
have profound effects on bone density placing patients
at increased risk for osteoporosis and fracture [22,28].
Further, several meta-analyses point to an association
between low serum testosterone levels and the metabolic
syndrome and diabetes [24-26]. Even acute withdrawal
of treatment in these men induces increased fasting
insulin levels and insulin resistance within two weeks
[27] while long-term hypogonadism carries heightened
prevalence of hyperinsulinemia, metabolic syndrome
and diabetes [42]. Thus, lack of or inadequate androgen
replacement may heighten further health risks for CHH
men such as cardiovascular morbidity. Accordingly,
these represent meaningful targets for interventions to
enhance adherence to treatment and self-management.
CHH patients have unmet psychosocial health needs
The online survey included several questions that were
developed to examine past interactions with healthcare
systems (Additional file 1) including experiences with
discrimination related to their condition [43]. Fewer
than one in five (16/105, 15%) of men reported that
they had faced this type of discrimination. Notably, ap-
proximately half of the respondents (54/105, 51%) had
been seen at a specialized/academic medical center. As
healthcare providers exert important interpersonal influ-
ences on health promoting behavior, we queried patients
about their experiences with healthcare professionals.
In total, 70/105 (67%) stated that their healthcare pro-
vider understood the medical aspects of their condition.
However, significantly fewer (39/104, 38%, p < 0.001)
perceived that their provider understood the emotional
impact of CHH. Having a provider who comprehended
the medical aspects of CHH correlated positively with
being seen at a specialized center (R = 0.40, p < 0.001)
while having a provider who understood patients’ feelings
about having CHH was positively correlated with having
been referred for psychological counseling (R = 0.22,
p < 0.05). The patient perspectives identified in the survey
suggest that while many CHH patients are able to find
and obtain specialized care/consultation with expertise in
handling the medical aspects of their care, the emotional
and psychological aspects of CHH are underappreciated.
Based on the survey findings we conducted three
patient focus groups (n = 26 total participants, mean age
37 ± 13, range 18–66, median 36 years) to explore the
challenges patients face in living with CHH and identify
facilitators of adaptive coping strategies that could
be leveraged for potential online interventions. What
emerged from these discussions were consistent, pervasivepsychological and emotional issues related to feelings of
isolation and shame (Figure 3). The mean age at diagnosis
was 18 ± 5 years (range 10–27, median 17 years) and
spending teenage years and young adulthood in a pre-
pubertal body was emotionally traumatic for many. In-
deed, many patients commented on their frustration with
what they perceived to be a late diagnosis or a delay in ini-
tiating treatment as well as significant concerns related to
underdeveloped genitalia. These experiences were linked
to 4 coherent themes: i) body image concerns, ii) low self-
esteem, iii) anxiety/depression, and iv) a sense of being
left-behind as their peers developed into adult bodies (and
adult roles) (Figure 3, Table 2). Themes were frequent and
their co-occurrence within and across groups suggest that
a saturation point had been reached. These unmet psycho-
social health needs indicate the need for psychological
support and represent targets for much-needed interven-
tion. Notably, differences were observed across different
national health systems. For instance, patients with nation-
alized health systems reported better continuity in care
(i.e. better transitions) and fewer gaps when changing
healthcare providers. In contrast, patients in individual
payer systems reported significant transition problems as
well as medication coverage issues both of which under-
mined adherence to treatment.
CHH patients have unmet health information needs
During focus group discussions, participants indicated that
healthcare providers (physicians, nurses and pharmacists)
Table 2 Table of themes emerging from focus group discussions, representative quotes, and targets for interventions
Theme Representative quotes Targets for interventions
Patient-Reported Challenges
Isolation "I was on the outside of any social group or gathering and on the inside, I was very
alone and depressed and isolated and very frightened"
connecting with others &
peer-to-peer support
"I realized that something was “wrong” with me, and didn’t know what, and it looked
like nobody knew. I more or less expected to have a unique disease which would have
my name."
"I’ve pretty much been in exile for the past ten years"
Shame
i. Body image
(the hardest part of CHH) "The body image problems really… I will have that until the
day I die"
"I can’t get undressed… I haven’t been swimming in many years. I can’t even pull my
sleeves up… I can’t sit there like you with your sleeves rolled up…I’ve got to keep
covered."
ii. ↓ Self-esteem
"I have a tough time engaging with people, talking with people. Usually, when I am
out in public I tend to look down at the ground, because you know… I feel so
ashamed"
cognitive- behavioral
interventions
"I always thought there was a big spotlight on me all the time. Just… self-conscious…
absolutely. I got a lot of bullying and being pushed around and abused when I was
young"
iii. Left behind
“I’m 40 years old and should be at the prime of my career and I don’t see myself…I
don’t know, it’s a psychological barrier that I can’t progress, I’m stuck "
"For Kallmann’s (CHH), it’s sort of a crucial sort of time you know, we say the
psychological and emotional things are equally as big as the medical forms of
treatment for it. That big, big thing (absent puberty) carries on for the rest of your life"
iv. Depression & anxiety
"I have depression, definitely. I have noticed a common denominator with depression
and self medication… myself included"
"…and my family, they weren’t supportive. They didn’t help me. So, I got depressed
and I tried to take my own life and then um…I left to seek help on my own"
Negative Healthcare Interactions
Lack of information
"The professor (doctor) who diagnosed my condition didn't even touch on the
psychological side of things"
online information &
resources
"For the first few years after it (CHH) was mentioned to me, there was nothing at all
coming back from the doctors. They didn’t really tell me what I was being treated for.
So it was kind of…they diagnosed me but didn’t tell me and anything"
"The doctors weren’t… it was just nothing. There was no real after-care at all after the diag-
nosis. It was just ‘you need to take these injections’ and that was that…you know, for the
rest of your life. There was no kind of…nothing. It was a lack of communication really"
Disregard for feelings
"I felt like I wasn’t considered intelligent enough to understand what I was being
treated for. It was like ‘oh, you won’t understand, it's complicated’. That’s it…yeah, it’s
not nice to be made to feel that way."
promoting patient-
centered approaches &
developing a "talking
sheet" to initiate
discussions with providers
"Somebody once said something to me, actually it was an endocrinologist, and I said
‘but I’m not normal’ you know? And this was several years ago, and I think he was
trying to say ‘look, everything will be alright, keep taking your medication and all the
rest of it’ and I said ‘I don’t know what normal is’…and that didn’t seem to faze him at
all. I sat here saying to this professional , educated, intelligent man - he’s a professor -
and I was saying ‘I don’t know what normal is’ and he didn’t respond. Nothing…he
didn’t even look at me."
"There’s no sense from anyone… about them trying to understand or even that it
crosses their mind that you are going through anything. You know, that it’s painful.
They are just ‘Mr. fix-it’ - give you a prescription and you are gone"
Lack of shared
decision-making
"He (doctor) didn’t give me any treatment options. He just said 'take this gel'. We didn’t
discuss what was the best treatment. I don’t know if it was just the physician that I went
to…maybe there are better ones out there who would have given me the option(s)"
"The first doctor I saw he said just take these and you’ll be ok"
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Table 2 Table of themes emerging from focus group discussions, representative quotes, and targets for interventions
(Continued)
Discordant expectations for
treatment outcome
"No one really explained to me…I thought that if I took the testosterone…I didn’t
understand that…I thought that if I just took the testosterone that I would go through
puberty and I would be normal." online anticipatory
guidance information"I said no, I can’t smell a thing and he said, 'Ah, you’ve got Kallmann's (CHH)!' I thought
wow that’s great, give me the injections and I can smell the roses and all that and well
of course it didn’t happen. My sense of smell never came."
The first column identifies thematic elements from the focus group discussions across two topic areas: patient-reported challenges and negative healthcare
interactions. The middle column presents representative quotes for the emergent themes. The third column lists the related targets for interventions to address
the unmet health and informational needs of the CHH men. Quotes referencing the term "Kallmann's" refers to Kallmann syndrome - the association of CHH with
the inability to smell (anosmia).
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adapt to living with CHH (Table 2). Providers who were
not forthcoming with information about CHH, disregarded
patient concerns/feelings, did not set appropriate expecta-
tions for treatment outcomes, and did not engage patients
in decisions, were sources of frustration for patients and
undermined patients’ sense of wellbeing. Healthcare pro-
fessionals could also be powerful promoters of adaptive
coping. Patients reported feeling supported by providers
who expressed empathy, facilitated self-management tech-
niques (i.e. self-injecting medications) and involved them
in decision making. As such, efforts to promote patient
participation in treatment decisions and providing patient
information and anticipatory guidance in lay language ap-
pear to be avenues for meeting patients’ informational
needs, and potentially improving patient satisfaction with
care and adherence.
CHH patients rely on the internet for CHH information
and peer-to-peer support
The survey participants were active users of the internet
for issues related to their condition. Nearly all partici-
pants (101/105, 96%) stated they had sought information
from online sources (i.e. Wikipedia). This may be related
to the fact that the manifestations of CHH (sexual im-
maturity and infertility) are very private and personal
matters and thus may contribute the high rate of an-
onymous information seeking that the internet provides.
Less than half of survey respondents (49/105, 47%) used
the medical literature as a resource for finding out about
CHH. This was interesting as these men have relatively
high levels of education (Table 1), yet preferred to seek
information from other online resources, paralleling the
increase in such practices among physicians [44]. Be-
cause the number of years of formal education may not
be the best predictor of facility with medical informa-
tion, we also used a previously validated self-report
question “How confident are you filling out medical
forms by yourself?” to screen those participants with in-
adequate healthcare literacy [33,34]. By this standard, all
but one of participants had adequate healthcare literacy.Therefore, despite adequate education, appropriate health-
care literacy and access to the literature (i.e. PubMed
Central [45]), it seems that patients are much more likely
to seek out information from online sources that are not
part of the medical literature. Therefore, providing expert-
reviewed information in lay language online could be an
effective way to disseminate CHH-related health informa-
tion to these dispersed patients.
The survey also revealed that patients seek informa-
tion from healthcare providers and the online commu-
nity in equal proportions (74/105, 70% and 81/105, 77%
respectively). Further, when asked to rate the importance
of healthcare professionals, online community and the
internet as sources for information, all rated similarly
(p = 0.58). These data support the notion that for CHH
patients, information from healthcare providers and
members of the online community who share their con-
dition are equally important and complementary. The
importance of connecting with other patients via the on-
line community was echoed in the patient focus groups.
Participants stated that connecting with other patients
online and finding out they were not alone was an im-
portant aspect of coming to terms with CHH, finding
meaning in their condition, and being able to not let
CHH dominate their life. Further, face-to-face encoun-
ters with other patients were often regarded as a pivotal
and life-changing event (Table 3).
The data from the present study are in line with the
findings of a 2011 report from the Pew Foundation that
identified patients with rare diseases as the most likely
group to draw upon online peer support network, even
more so than those with other, more common chronic
health conditions [6]. Patient knowledge is different
from that of professional healthcare providers. Patient
expertise grows from a personal day-to-day experience
of living with a condition and as such, patients can pro-
vide critical informational support for coping and man-
aging one’s health [46]. These complementary realms
of expertise present an opportunity for collaborative
efforts for health promotion and improving quality of
life for patients dealing with chronic conditions [47-49].
Table 3 Patient-reported facilitators of coping
Theme Representative quotes Targets for interventions
Meeting others &
online support
“Though I have a loving family I had spent most of my life feeling depressed, confused, lonely,
alone, isolated, and frequently in despair.
In just a couple of hours at the meeting 3 years ago… those feelings decreased. For the first
time ever I was with a group of people with whom I felt normal and at ease, valued and
respected. This has made a tremendous difference in my life."
Online peer-to-peer
support
"It wasn’t until I found other people like (patient community leader) that I kind of filled in the
blanks a bit. It was quite isolating for me and I had no one to talk to and I felt like I was the
only person in the world to have this problem"
"I’ve really felt alone. So I went online, on Facebook just to see if there was something or a
meeting and I found this group and it was the best thing I ever did because I found out there
are other people and I thought I was alone. But I found others… which is really good"
"Going to my first Kallmann (CHH) meeting about 6 years ago… and until then, I was totally in
the dark. And when I met up with fellow patients, I realized I’m not on my own"
Coming to terms
with CHH
“Get over it, take matters into your own hands… you will get help. All you have to do is ask
for it. (To the moderator) in your research, you are searching for ways that would help me… a
toolkit, a fact sheet ‘living with Kallmann (CHH)’ that kind of thing…it also involves emotional
things. If you can give that to a doctor so then that is the trigger to start a conversation. Then
you can take matters into your own hands”.
Patient empowerment"So it was a change in mentality, being taunted as a child then I realized that I had to do
certain things to get my life back"
"It was just the things that I would have to find out about myself that no one could tell me…
and like I said, (patient community leader) has helped… Both on a personal level and for the
research into the condition itself. But, being able to live with it is a very personal thing that I
think you need to find out for yourself…and I think I’m coming along pretty nicely… I’m not
letting it rule my life quite so much as I used to."
Positive healthcare
interactions
"All the medical professionals I have been working with…I’ve been very lucky because they have
always been very helpful and considerate about it. So, I guess I have been fortunate that way"
Promoting patient-
centered approaches
& developing a "talking
sheet" to initiate
discussions with
providers
"Definitely, self-injecting (helped). Learning about the syndrome made me feel that Kallmann
(CHH) is not such a big deal. But in my case, it was not enough… and the psychotherapy
aspect helped a lot"
"I first heard about Kallmann's (CHH) at 25 when I moved in a new city and changed
endocrinologists. That made a huge difference, suddenly she made it sounds like it was not
such a big deal. In my experience female doctors are more easy to talk with, tend to ask more
about how it works in the everyday life, and involve us in our prescriptions"
The first column identifies the central emergent themes from focus group discussions related to effective coping. The middle column presents representative
quotes. The third column identifies potential avenues for interventions to promote coping and resilience among CHH men. *Quotes referencing the term
"Kallmann's" refers to Kallmann syndrome - the association of CHH with the inability to smell (anosmia).
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cause it can diminish the isolation of living with a rare
condition. Further, such peer-to-peer support may hold
important promise for very practical and concrete bene-
fits such as promoting adherence to treatment and con-
tinuity with healthcare and encouraging peers to seek
mental health services when needed.
CHH patients are receptive to online interventions
Focus group participants were unanimously open to and
in support of utilizing online approaches to help develop
coping and self-management skills. The only concern
raised regarding this was the issue of confidentiality that
perhaps is not surprising given the very private nature of
the sexual immaturity and infertility of CHH. This mixed-
methods study identified a variety of unmet health needs
of CHH men. Importantly, the focus groups revealed posi-
tive examples of patients overcoming challenges, findingmeaning in their condition and becoming empowered, ac-
tivated patients (Table 3). As these men are active internet
users and receptive to the idea of online interventions, we
propose several patient-centered approaches for health
promotion in these dispersed patients.
Developing online interventions to address the needs
of CHH patients
Interventions addressing the identified shortfalls in care
for CHH patients are intended to enhance wellness and
improve coping and quality of life for these individuals.
This is the fundamental objective of health promotion –
the process of enabling people to overcome health chal-
lenges and increase control over their situation to
achieve greater health [50]. Indeed, the Health Promo-
tion Model [51] has been used as a model to develop
patient-centered approaches to activate and empower
patients for self-management [52] and thus seems fit the
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tient expertise and dramatically reframes patient involve-
ment as well as the role of the healthcare professionals
to redefine successful health outcomes [53]. Herein we
identify three main targets for health promoting inter-
ventions (Tables 2 and 3).
First, CHH patients have unmet informational needs
related to their condition. Given their active internet
use, it seems logical to launch web-based information re-
sources for patients and providers alike. For patients,
this could include information in lay language about
CHH, treatment options, and anticipatory guidance re-
lated to treatment (i.e. what to expect from treatment
and in what timeframe). Further, we propose to develop
materials (i.e. fact sheet of discussion points) for health-
care professionals, written by expert clinicians and avai-
lable online for patients to use in order to initiate
discussions with their healthcare provider on the psy-
chological and emotional aspects of the condition and to
promote shared decision-making. These materials would
help contribute to create a virtual online empowerment
toolkit for patients to learn about their condition, find
expert care, and become empowered to take control of
their health. Further, these resources could be provided
in multiple languages via the European network studying
GnRH deficiency [30] encompassing patient information
in lay language, listings of specialized referral centers,
genetic testing resources, clinical trial listings, and web-
based platforms for contacting expert clinicians as well
as links with peer-to-peer support.
Second, enhancing online peer-to-peer support to di-
minish the sense of isolation, share coping strategies and
encourage peers to seek mental health services when
needed to address issues of anxiety/depression. The syn-
ergy of online connectivity and patient expertise facili-
tates crowdsourcing for the rare disease community.
Crowdsourcing is the process of tapping into the collect-
ive knowledge and problem solving abilities of a group
(such as patients with a shared medical condition) to
generate ideas and solutions [54]. Importantly, online
patient communities are not intended to replace existing
healthcare infrastructures, rather their expertise differs
from healthcare professionals and can be valuable for
peer-to-peer support and learning how to deal with issues
on a daily basis [46]. Further, this pool of knowledge/ex-
perience not only impacts health management, but is also
beginning to change approaches to research [55].
Third, to help patients address their feelings of shame,
body image concerns and low self-esteem there is an
opportunity to utilize online cognitive-behavioral inter-
ventions. Indeed, online education combined with peer-
to-peer coaching has been successful in enhancing
self-management and adherence to treatment for bipolar
disorder and diabetes [56,57]. A similar approach combiningonline patient education, cognitive behavioral interven-
tions, and peer coaching could be adapted to address the
specific body-image and self-esteem issues related to CHH.
Further, technology may enable contact with otherwise dif-
ficult to reach patients and potentially surmount barriers
that exist for face-to-face mental health treatment.
Limitations
Like other studies of this kind, this needs assessment has
limitations. First, the inferences drawn from the survey
findings could be strengthened by a larger sample size.
Indeed, recruiting adequate numbers of rare disease pa-
tients can pose a challenge. This is why we utilized a
web-based approach, yet this is not without bias as not
everyone has internet access and is perhaps reflected in
the fact that respondents were highly educated. Further,
an online survey in English may introduce a potential
Anglophone bias. Importantly, the longstanding critique
of online research (access) is beginning to fade as the
number of individuals lacking internet access rapidly
shrinks. As of 2011, 73% of European Union households
had internet access (2/3 of which have broadband). Fur-
ther, more than half of Europeans use the internet daily
and just one quarter (24%) have never used the internet
[58] and many developing countries have “leapfrogged”
straight into mobile handsets for multimodal communi-
cation and connectivity [59].
Second, there are potential biases in the sampling of
subjects. Participants were recruited via expert clinicians
as well as among patient support groups. As medical
record review was not part of this study, we recontacted
40% of respondents to confirm diagnosis. As such, we
cannot be sure that every respondent met all hormonal
and clinical criteria of a CHH diagnosis. However, the
fact that the findings of the survey were mirrored in the
focus groups (where all participants had confirmed CHH
diagnosis) contributes to the validity of the study. Add-
itionally, engaging patients in the study development
and conducting an internet survey introduces sources of
potential bias as these patients are the ones who seek
out forums and web-based support. Similarly, those par-
ticipating in patient support groups could represent men
who are struggling most to deal with their condition and
thus may overestimate the difficulties experienced by
men with CHH. However, these issues may be less of a
concern for such a needs assessment as the intent was
precisely to identify a specific cohort of patients to ex-
plore their situation and perspectives in depth. While
not a random sampling of patients, targeting internet
users was necessary to assess the acceptability of deliver-
ing web-based interventions to patients who use the
internet as a resource for health information and sup-
port. In addition, the anonymity of online information
can be an asset for eliciting information that patients
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counters with healthcare providers [60].
Third, the evaluation of adherence is often debated as
there is no gold standard definition, no clear consensus
on what is an acceptable level of adherence and self-
report is subjective and an inherently flawed method. An
alternative approach would be to perform retrospective
chart reviews and comb pharmacy refill information, but
these are beyond the scope of this needs assessment
study. Rather, this survey was intended to capture a glo-
bal picture adherence patterns in this patient population.
The rationale for using a self-report measure was based
on the fact that CHH is a chronic condition and as such,
patients are responsible for the bulk of their care. There-
fore, understanding patient perceptions and perspectives
is a critical first step in developing patient-centered
approaches to activate individuals and enhance self-
management of their chronic condition.
Conclusions
Patients with CHH often have long gaps in care and strug-
gle with significant psychosocial sequelae that are often
unrecognized by the healthcare community. These pa-
tients are active internet users who draw on social media
and online communities for support and to complement
the information received from healthcare professionals.
Patients are receptive to online interventions aimed at ad-
dressing their unmet needs. Peer-to-peer support can help
enhance coping and patients should be encouraged to
utilize these online communities. Drawing upon patient
expertise and developing partnerships with online patient
communities may provide new opportunities for health
promotion and improved quality of life for these patients.
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